To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
News
Researchers at SHFJ and NeuroSpin applied a passive MRI elastography sequence to patients with brain tumors. This non-invasive approach provided information on tumor stiffness and nature, and could support early detection, surgical planning, and treatment monitoring.
Researchers from SPI (DMTS) developed a formulation of PLGA nanoparticles loaded with the anticancer trastuzumab (NP-TZB) and measured their ability to cross a cellular model of the nasal epithelial barrier. This first validated step supports a potential nose-to-brain (N2B) delivery route.
A team from SIMoS (DMTS) has demonstrated the ability of a peptide derived from a spider venom toxin to detect overexpressed sodium channels in a metastatic non-small cell lung cancer (NSCLC) cell line.
The COVID-PATH project was officially launched on March 12, 2025, to investigate the gastrointestinal impact of SARS-CoV-2 and its link to Long COVID.
As a stakeholder in the NOMATEN Centre of Excellence for innovative multifunctional materials, the CEA-Joliot Institute supports its development by regularly organizing training sessions for its staff. The latest examples.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.